Differentiation and Reversal of Malignant Changes in Colon Cancer Through PPARgamma

Nat Med. 1998 Sep;4(9):1046-52. doi: 10.1038/2030.

Abstract

PPARgamma is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPARgamma is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPARgamma ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARgamma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / physiopathology*
  • Animals
  • Cell Differentiation
  • Cell Division
  • Chromans / pharmacology
  • Colonic Neoplasms / physiopathology*
  • Gene Expression
  • Humans
  • Ligands
  • Mice
  • Mice, Nude
  • Receptors, Cytoplasmic and Nuclear / agonists
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / physiology*
  • Thiazoles / pharmacology
  • Thiazolidinediones*
  • Transcription Factors / agonists
  • Transcription Factors / genetics
  • Transcription Factors / physiology*
  • Troglitazone
  • Tumor Cells, Cultured

Substances

  • Chromans
  • Ligands
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • Troglitazone